クローン病を合併した残存小腸１２０ｃｍの急性前骨髄球性白血病患者における経口トレチノイン（ａｌｌ‐ｔｒａｎｓ ｒｅｔｉｎｏｉｃ ａｃｉｄ：ＡＴＲＡ）の体内動態
スポンサーリンク
概要
- 論文の詳細を見る
Tretinoin (All-trans retinoic acid : ATRA) is the drug of choice for the remission induction treatment of acute promyelocytic leukemia (APL). Its action against APL cells involves the degradation of promyelocytic leukemia-retinoic acid receptor α (PML-RARα) protein which represses their cellular differentiation.We treated a 44-year-old Japanese male patient with APL using orally administered ATRA. He had previously undergone multiple resections of the bowels due to Crohn's disease and his residual intestine length was only 120 cm. In order to investigate the pharmacokinetics of ATRA in this patient, we measured the plasma concentrations. On the 11th day of orally administering ATRA twice a day, the maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC0-12) of ATRA were 51.9μg/L and 460μg·h/L, respectively. These data are comparable with those for patients without gastrointestinal complications, indicating that ATRA was sufficiently absorbed in spite of the patient having such a short intestine. Complete remission was achieved by the course of ATRA treatment.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)